NCT03729297 - Cabozantinib in Advanced Salivary Gland Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

November 6, 2019

Study Completion Date

November 6, 2019

Conditions

Salivary Gland Cancer

Interventions

DRUG

Cabozantinib

cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.

Trial Locations (1)

6500HB

Radboudumc, Nijmegen